Interleukin-17
Guselkumab exhibits comparable efficacy to IL-17A, TNF inhibitors for psoriatic arthritis
Novel therapies provide options for patients with spondyloarthritides
Bimekizumab meets primary, secondary endpoints in phase 3 psoriasis study
Guselkumab efficacious for joint, skin symptoms, physical function in PsA
ATLANTA — Guselkumab, administered either every 4 or 8 weeks, is efficacious for joint and skin symptoms, as well as physical function and quality of life, among patients with active psoriatic arthritis who are biologic-naive or previously received TNF inhibitors, according to data presented at ACR/ARP 2019.
Top stories for World Psoriasis Day: ‘More than a day for awareness’
UCB reports bimekizumab response rates superior to Stelara in psoriasis
Treatment with bimekizumab, an interleukin-17A and IL-17F inhibitor in adults with chronic plaque psoriasis, resulted in at least a 90% improvement in the Psoriasis Area and Severity Index and Investigator Global Assessment score of clear or almost clear, according to phase 3 results from the development program BE VIVID by UCB.